



FIGURE 1A



00955001 041604

FIGURE 1C




[illegible]

FIGURE 2B

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

Fig. 2. a. and b. are views of the same area.

FIGURE 3





FIGURE 4



□ 1.56 µg; ○ 0.78 µg V1J:gD DNA; ◆ saline

Δ 200, 100, 25, 12.5,
6.25, 3.13 µg

FIGURE 5




FIGURE 6

Effect of V1Jns:gB Immunization on HSV Infection [gB I]





FIGURE 7

WLM 93.9

Challenge of gC and ICP27 (DNA) Immunized Mice



Immunized 0, 7 weeks
challenged 11 weeks
(≈ 5.65 logs HSV2 IP)

FIGURE 8

<u>Group^a</u>	<u>Survivors/ Total (%)</u>	<u>Mean Day to Death</u>	<u>Paralyzed/ Total (%)</u>	<u>Vaginal Virus Titer^b</u>		
				<u>Day 2^c</u>	<u>Day 4</u>	<u>Day 6</u>
Vaccine, 10 µg	8/10 (80)	12.5 ± 0.7	5/10 (50)	3.8 ± 1.9	2.3 ± 1.2	<1.5 ± 0.0
Vaccine, 100 µg	10/10 (100) [†]	>21	0/10 (0)*	3.0 ± 1.3 ^ø	2.0 ± 0.7 [†]	<1.5 ± 0.0
Placebo	6/10 (60)	14.8 ± 4.0	8/10 (80)	5.0 ± 2.3	3.1 ± 1.4	1.6 ± 0.3

a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

b Log10 cell culture infections doses per ml, determined from vaginal swabs.

c After virus inoculation.

* P<0.001.

† P=0.008, ø P=0.06.

FIGURE 9

Effect of V1J:gD Immunization on HSV Vaginal Lesions in Guinea Pigs







FIGURE 10




103410-6692300

FIGURE 11



FOOT 653680

FIGURE 12



FOSTER 6695860

FIGURE 13




FIGURE 14





FIGURE 15

